Q2 2026 Aug 15, 2026

Shares declined 0.8% following Q2 results as investors weighed early clinical progress against limited commercial traction and cautious near-term catalysts.

Key takeaways

Initiated randomized Phase 2 study of agenT-797 in acute lung injury and ARDS patients in Ukraine under challenging conditions.
Early non-comparative data showed patients alive and fever-free at day 28 with signs of improved oxygenation and inflammation markers; however, data remain preliminary and require validation in ongoing randomized trial.
No serious adverse events attributed to agenT-797, supporting initial safety profile.
Launched first international named patient access program in Brazil, creating a paid, physician-directed pathway outside of clinical studies, but this is not a commercial launch.
U.S. site activations for the Phase 2 trial are underway with additional clinical data expected in early 2027, leaving near-term inflection points limited.

Q1 2026 May 16, 2026

Shares rose modestly by 2.0% following the earnings update as the company highlighted ongoing clinical progress and new trial initiations, though the market showed restraint, indicating results and developments were broadly in line with expectations without clear breakthroughs.

Key takeaways

Presented Phase II clinical data for refractory gastric cancer showing prolonged median overall survival beyond 23 months in a heavily pretreated, checkpoint-refractory patient population.
Introduced a randomized Phase II trial for severe acute lung injury and ARDS, designed with a seamless Phase II/III pathway to accelerate potential registrational development.
Highlighted translational findings demonstrating the platform’s mechanistic immune modulation versatility across distinct disease areas including cancer and severe lung injury.
Announced a strategic collaboration to advance targeted TCR engineered iNKT therapies for pediatric cancers, aiming to leverage off-the-shelf cell therapy advantages in a high-need area.
Safety profile across approximately 100 patients treated remains favorable with no new red flags noted, supporting continued clinical development.

Q3 2025 Nov 14, 2025

MiNK Therapeutics achieved significant clinical milestones in Q3 2025, demonstrating promising survival outcomes for patients with relapsed or refractory cancers through its investigational AGENT-797 therapy, while strengthening collaborations and enhancing its operational independence.

Key takeaways

AGENT-797 therapy demonstrated a remarkable median overall survival of approximately 23 months in patients treated for resistant solid tumors, far exceeding expectations for this patient cohort.
The therapy exhibited a strong safety profile, with no major toxicities observed, underscoring its potential as a viable treatment option in challenging cancer cases.
MiNK has established strategic partnerships with the University of Wisconsin and received significant funding support for advancing its iNKT cell therapy platform, aimed at improving outcomes post-stem cell transplantation.
The company's leadership was strengthened with the appointment of Dr. John Holcomb to the Board, enhancing its strategic vision in clinical development and partnerships.
MiNK Therapeutics is positioned as a leader in the allogeneic iNKT cell space, bolstered by its scientific advancements and disciplined capital utilization.

MiNK Therapeutics Inc. Common Stock Earnings Recaps

Keep exploring